Valuation: THX Pharma

Market Cap 47.56M 52.35M 43.94M 39.69M 74.9M 4.92B 77.54M 528M 209M 2.64B 196M 192M 8.36B P/E 2024
-2.8x
P/E 2025 -9.84x
Enterprise Value 42.67M 46.97M 39.43M 35.61M 67.21M 4.41B 69.58M 474M 188M 2.37B 176M 173M 7.5B EV / Sales 2024
2.8x
EV / Sales 2025 30.6x
Free-Float
89.81%
Yield 2024 *
-
Yield 2025 -
1 day-1.51%
1 week-1.80%
Current month-1.21%
1 month+4.47%
3 months-19.85%
6 months-6.70%
Current year+52.80%
1 week 3.19
Extreme 3.19
3.58
1 month 3.04
Extreme 3.045
3.58
Current year 1.83
Extreme 1.83
5.1
1 year 1.49
Extreme 1.49
5.1
3 years 0.26
Extreme 0.2605
5.1
5 years 0.26
Extreme 0.2605
7.04
10 years 0.26
Extreme 0.2605
23.6
Manager TitleAgeSince
Chief Executive Officer - 01/01/2023
Director of Finance/CFO - 01/04/2024
Chief Tech/Sci/R&D Officer - 19/10/2021
Director TitleAgeSince
Director/Board Member - 31/03/2024
Chairman - 31/03/2024
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap. Importance
3/4/26 Buy

Chief Operating Officer

2,825 0.0195%
3/4/26 Buy

Chief Operating Officer

4,488 0.0310%
3/4/26 Sell

Chief Operating Officer

4,944 0.0342%
Change 5-day change 1-year change 3-year change Capi.($)
-1.51%-1.80%+69.87%+181.41% 53.28M
-1.29%-1.76%+51.98%+64.66% 66.33B
-0.09%+2.79%+12.54%+95.02% 60.62B
+0.63%+1.64%+23.11%+89.70% 55.5B
-1.26%-1.45%+12.43%+117.42% 47.58B
-0.15%-5.06%+20.00%+29.27% 43.69B
-3.15%-16.63%+146.30%+685.27% 37.27B
+0.23%+1.66%+14.85%+49.06% 36.57B
+2.35%-3.61%+80.65%+60.70% 32.22B
+1.42%+5.84%-36.40%+402.78% 26.58B
Average -0.28%-1.02%+39.53%+177.53% 41B
Weighted average by Cap. -0.29%-1.12%+35.89%+152.30%

Financials

2024 2025
Net sales 2.28M 2.51M 2.11M 1.91M 3.6M 236M 3.72M 25.37M 10.05M 127M 9.43M 9.23M 401M 806K 887K 745K 673K 1.27M 83.31M 1.31M 8.96M 3.55M 44.71M 3.33M 3.26M 142M
Net income -1.77M -1.94M -1.63M -1.47M -2.78M -182M -2.88M -19.61M -7.77M -97.9M -7.29M -7.14M -310M -3M -3.3M -2.77M -2.51M -4.73M -310M -4.89M -33.35M -13.21M -166M -12.4M -12.14M -527M
Net Debt 1.9M 2.1M 1.76M 1.59M 3M 197M 3.11M 21.16M 8.39M 106M 7.87M 7.7M 335M -4.88M -5.38M -4.51M -4.08M -7.69M -505M -7.96M -54.27M -21.5M -271M -20.17M -19.75M -858M
Projected Income Statement - Annual - THX Pharma
Logo THX Pharma
THX Pharma (formerly Theranexus) is an innovative biopharmaceutical company that emerged from the French Atomic Energy Commission (CEA) and specializes in the treatment of neurological diseases and pioneer in the development of drug candidates targeting both neurons and glial cells. THX Pharma has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.
Employees
12
Date Price Change Volume
16/11/26 EUR 3.270 -1.51% 47,821
13/11/26 EUR 3.320 -4.60% 50,135
12/11/26 EUR 3.480 -0.57% 41,651
11/11/26 EUR 3.500 +2.34% 63,677
10/11/26 EUR 3.420 +2.70% 41,196
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.270EUR
Average target price
5.800EUR
Spread / Average Target
+77.37%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - THX Pharma
  1. Stock Market
  2. Stocks
  3. ALTHX Stock